A controlled study with Dihydergot on patients with orthostatic dysregulation.
(1) 36 outpatients with a manifest orthostatic syndrome were the subject of a double-blind study to investigate the influence of Dihydergot and a placebo over a 4-week period. (2) In the majority of subjects, the dosage was 1 tablet (2.5 mg) 3 times a day. (3) In the test group with Dihydergot (17 subjects), a normalization of circulatory regulation occurred in all cases. (4) In contrast, the placebo group (19 patients) showed no changes. (5) The subjective complaints of which only a part can be attributed to the orthostatic syndrome, largely disappeared through the treatment with Dihydergot, while those in the placebo group were not altered. This may be explained by the central stabilizing effect of Dihydergot which complements the hemodynamic properties.
D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004087:Dihydroergotamine / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004879:Ergotamines; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007024:Hypotension, Orthostatic / Q000188:drug therapy*; D010919:Placebos; D013997:Time Factors
D004879:Ergotamines; D010919:Placebos; D004087:Dihydroergotamine